Methotrexate
Contents
Description
Methotrexate is an antimetabolite and antifolate drug used in the treatment of gestational trophoblastic neoplasms including choriocarcinoma and hydatidiform mole. It inhibits dihydrofolate reductase, preventing DNA synthesis in rapidly dividing cells. Methotrexate has been a cornerstone of treatment for low-risk gestational trophoblastic disease for decades.
Indications & Therapeutic Use
Gestational trophoblastic neoplasm, choriocarcinoma, hydatidiform mole, rheumatoid arthritis, psoriasis
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Methotrexate — GNH India
387 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | Methotrexate |
| Brands | 1 brand available |
| Active Ingredient | Methotrexate |
| Drug Class | Gestational trophoblastic neoplasm |
| Manufacturer | Multiple manufacturers |
| Dosage Forms | Oral tablet 2.5mg, 5mg, 7.5mg, 10mg, 15mg; Injectable solution 25mg/mL |
| Medical Code | L01BA01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 3 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00339235 |
| Countries | 9 countries |